Objectives
-
Identify drugs associated with alterations in weight and their subsequent effect on growth.
-
Understand varying taste alterations and their effect on nutrition intake.
-
Recognize the differing drugs’ mechanisms of action or their adverse effects and the varying nutritional complications which may ensue.
Key Words
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Boullata JI. Influence of medication on nutritional status. In: Bendich A, Deckelbaum RJ, eds. Preventive nutrition: the comprehensive guide for health professionals, 3rd ed. Totowa, NJ: Humana Press, 2005:833–868.
Leslie WS, Hankey CR, Lean MEJ. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJ Med 2007;100:395–404.
Pischon T, Sharma AM. Use of beta-blockers in obesity hypertension: potential role of weight gain. Obes Rev 2001;2:275–280.
ESHRE Capri Workshop Group. Continuation rates of oral contraceptives and hormone replacement therapy. Human Reproduction 2000;15:1865–1871.
Umbricht D, Kane J. Medical complications of new antipsychotic drugs. Schizophrenia Bulletin 1996;22:475–483.
Kusumakar V. Antidepressants and antipsychotics in the long-term treatment of bipolar disorder. J Clin Psychiatry 2002;63 Suppl 10:23–28.
Vanina Y, Podalskaya A, Sedky K et al. Body weight changes associated with psychopharmacology. Psychiatr Serv 2002;53:842–847.
Savient Pharmaceuticals, Inc. Oxandrin (oxandrolone tablets, USP) prescribing information. East Brunswick, NJ, 2005. Available from: http://www.fda.gov/cder/foi/label/2005/013718s023lbl.pdf.
James J. Marijuana safety study completed: weight gain, no safety problems. AIDS Treat News 2000;348:3–4.
Mulligan K, Schambelan M. Anabolic treatment with GH, IGF-1, or anabolic steroids in patients with HIV-associated wasting. Int J Cardiol 2002;85:151–159.
Berenstein EG, Ortiz Z. Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2005;18:CD004310.
Bhasin S, Parker RA, Sattler F, et al. Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity. J Clin Endocrinol Metab 2007;92:1049–1057.
Davies KM, Heaney RP, Recker RR, Barger-Lux MJ, Lappe JM. Hormones, weight change and menopause. Int J Obes Relat Metab Disord 2001;25:874–879.
Yüksel H, Odabaşi AR, Demerican S, et al. Effects of oral continuous 17?-estradiol plus norethistrone acetate replacement therapy on abdominal subcutaneous fat, serum leptin levels and body composition. Gynecol Endocrinol 2006;22:381–387.
Yüksel H, Odabaşi AR, Demerican S, Köseoğlu K, Kizilkaya K, Onur E. Effects of postmenopausal hormone replacement therapy on body fat composition. Gynecol Endocrinol 2007;23:99–104.
Coney P, Washenik K, Langley RG, DiGiovanna JJ, Harrison DD. Weight change and adverse event incidence with low-dose oral contraceptive: two randomized, placebo-controlled trials. Contraception 2001;63:297–302.
Golinko BE. Side effect of dextroamphetamine and methylphenidate in hyperactive children- a brief review. Prog Neuropsychopharmacol Biol Psychiatry 1984;8:1–8.
Halford JCG, Harrold JA, Boyland EJ, Lawton CL, Blundell JE. Serotonergic drugs. Drugs 2007;67:27–55.
Tonstad S, Tykarski A, Weissgarten J, et al. Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension. Am J Cardiol 2005;96:243–251.
Dolberg OT, Barkai G, Gross Y, Schreiber S. Differential effects of topiramate in patients with traumatic brain injury and obesity – a case series. Psychopharmacol 2005;179:838–845.
Bowden CL, Calabrese JR, Ketter TA, Sachs GS, White RL, Thompson TR. Impact of lamotrigine and lithium on weight in obese and nonobese patients weith bipolar I disorder. Am J Psych 2006;163:1199–1201.
Greenberg JA, Boozer CN, Geliebter A. Coffee, diabetes, and weight control. Am J Clin Nutr 2006;84:682–693.
Levine JA, Lanningham-Foster LM, McCrady SK et al. Interindividual variation in posture allocation: possible role in human obesity. Science 2005;307:584–586
Perkins KA, Sexton JE, DiMarco A. Acute thermogenic effects of nicotine and alcohol in healthy male and female smokers. Physiol Behav 1996;60:305–309.
Safer DJ, Allen RP, Barr E. Growth rebound after termination of stimulant drugs. J Pediatr 1975;86:113–116.
Huffman GB. Evaluating and treating unintentional weight loss in the elderly. Am Fam Physician 2002;65:640–650.
Markley EJ, Mattes-Kulig DA, Henkin R. A classification of dysgeusia. J Am Diet Assoc 1998:83:578–580.
Ackerman BH, Kasbekar N. Disturances of taste and smell induced by drugs. Pharmacotherapy 1997;17:482–496.
Bartoshuk LM, Beauchamp GK. Chemical senses. Annu Rev Psychol 1994;45:419–449.
Micromedex Healthcare Series. Available at: http://healthcare.micromedex.com.
Mott AE, Leopold DA. Disorders of taste and smell. Med Clin North Am 1991;75:13231–13253.
Davies AN, Daniels C, Pugh R et al. A comparison of artificial saliva and pilocarpine in the management of xerostomia in patients with advanced cancer. Palliat Med 1998;12:105–111.
Soderling E, Le Bell A, Krstila V et al. Betaine-containing toothpaste relieves subjective symptoms of dry mouth. Acta Odontol Scand 1998;56:65–69.
Henkin RI, Schecter PJ, Friedewald WT, Demets DL, Raff M. A double blind study of the effects of zinc sulfate on taste and smell dysfunction. Am J Med Sci 1976;272:285–299.
Souder E, Yoder L. Olfaction: the neglected sense. J Neurosci Nurs 1992;24:273–280.
Taylor AT. Nausea and vomiting. In: DiPiro JT, ed. Pharmacotherapy: a pathophysiologic approach, 5th ed. New York: McGraw-Hill, 2002:641–653.
Rollins CJ. General pharmacologic issues. In: Matarese LE, ed. Contemporary nutrition support practice: a clinical guide. Philadelphia: W.B. Saunders, 1998:303–332.
Foss JF. A review of the potential role of methylnaltrexone in opioid bowel dysfunction. Am J Surg 2001;182:19S–26S.
Taguchi A, Sharma N, Saleem RM, et al. Selective postoperative inhibition of gastrointestinal opioid receptors. N Engl J Med 2001;345:935–940.
Cohen D, Grobbee DE, Stolk RP, Gispen-de Wied, CC. Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders. Diabetes Care 2006;29:786–791.
Mills GA, Horn JR. Beta-blockers and glucose control. Drug Intell Clini Pharm 1985;19:246–251.
Skouby SO. Oral contraceptives:hormonal dose and effects on carbohydrate metabolism. Maturitas 1988;1(suppl):111–115.
Burroughs TE, Lentine KL, Takemoto SK, et al. Influence of early posttransplantation prednisone and calcineurin inhibitor dosages on the incidence of new-onset diabetes. Clin J Am Soc Nephrol 2007;2:517–523.
Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008;doi:10.1681/ASN.2007111202.
Luna B, Feinglos MN. Drug-induced hypoglycemia. JAMA. 2001 Oct 24–31;286:1945–1948.
Van Hooff JP, Christiaans MH. Use of tacrolimus in renal transplantation. Transplant Proc 1999;31:3298–3299.
Lodise T, Graves J, Miller C, Mohr JF, Lomaestro B, Smith RP. Effects of gatifloxacin and levofloxacin on rates of hypoglycemia and hyperglycemia among elderly hospitalized patients. Pharmacotherapy 2007;27:1498–1505.
Marks V, Teale JD. Drug-induced hypoglycemia. Endocrinol Metab Clin North Am 1999;28:555–577.
Bunout D. Nutritional and metabolic effects of alcoholism: their relationship with alcoholic liver disease. Nutrition 1999;15:583–589.
Pollak PT, Mukherjee SD, Fraser AD. Sertraline-induced hypoglycemia. Ann Pharmacother 2001;35:1371–1374.
Meertens J, Monteban-Kooistra WE, Ligtenberg J, Tulleken, JE, Zijlstra JG. Severe hypoglycemia following venlafaxin intoxication. J Clin Psychopharmocol 2007:27:414–415.
Chan JC, Cockram CS, Critchley JA. Drug-induced disorders of glucose metabolism. Mechanisms and management. Drug Saf 1996;15:135–157.
Mantel-Teeuwisse AK, Kloosterman JM, Maitland-van der Zee AH, Klungel OH, Porsius AJ, de Boer A. Drug-induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Saf 2001;24:443–456.
Strobl JS, Thomas MJ. Human growth hormone. Pharmacol Rev 1994;46:1–34.
Kupfer SR, Underwood LE, Baxter RC, et al. Enhancement of the anabolic effects of growth hormone and insulin-like growth factor-1 by use of both agents simultaneously. J Clin Invest 1993;91;391–396.
Hausmann DF, Nutz V, Rommelsheim K, et al. Anabolic steroids in polytrauma patients. Influence on renal nitrogen and amino acid losses: a double blind study. J Parent Enter Nutr 1990;14:111–114.
Hansel DT, Davies JWL, Shenkin A, et al. The effects of an anabolic steroid and peripherally administered intravenous nutrition in the early postoperative period. J Parent Enter Nutr 1989;13:349–357.
Demling RH, DeSanti L. Oxandrolone, an anabolic steroid, significantly increases the rate of weight gain in the recovery phase after major burns. J Trauma 1997;43:47–51.
Hengge UR, Baumann M, Maleba R, et al. Oxymetholone promotes weight gain in patients with advanced human immunodefiency virus (HIV-1) infection. Sr J Nutr 1996;75:129–138
Wolthers OD. Inhaled corticosteroids and growth. J Pediatr Endocrinol Metab 2001;14:1487–1490.
Pelton R, LaValle JB, Hawkins EB, Krinsky DL (eds). Drug-induced nutrient depletion handbook, 2nd ed. Hudson, OH: Lexi-Comp, Inc, 2001.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Gervasio, J.M. (2009). Drug-Induced Changes to Nutritional Status. In: Boullata, J., Armenti, V. (eds) Handbook of Drug-Nutrient Interactions. Nutrition and Health. Humana Press. https://doi.org/10.1007/978-1-60327-362-6_15
Download citation
DOI: https://doi.org/10.1007/978-1-60327-362-6_15
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60327-363-3
Online ISBN: 978-1-60327-362-6
eBook Packages: MedicineMedicine (R0)